We can’t show the full text here under this license. Use the link below to read it at the source.
Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2
Glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors in people with type 2 diabetes and ischemic stroke
AI simplified
Abstract
The absolute risk of a very severe stroke was 2.4% in patients with type 2 diabetes treated with GLP-1 receptor agonists compared to 6.1% for those treated with DPP-4 inhibitors.
- Users of GLP-1 receptor agonists had a lower risk of very severe stroke than users of DPP-4 inhibitors, with an adjusted risk ratio of 0.49.
- The adjusted risk ratio for 30-day mortality in GLP-1RA users was 0.55, indicating a potential reduction in short-term mortality.
- For 365-day mortality, the adjusted risk ratio was 0.72, suggesting a possible decrease in long-term mortality among GLP-1RA users.
- Findings indicate that treatment with GLP-1 receptor agonists may be associated with improved outcomes after an in patients with type 2 diabetes.
AI simplified
Key numbers
2.4%
Absolute Risk of Very Severe Stroke
Absolute risk in GLP-1RA users compared to DPP-4i users.
3.9%
30-Day Mortality Rate
Mortality rate for GLP-1RA users compared to 10.0% for DPP-4i users.
0.49
Adjusted Risk Ratio for Very Severe Stroke
Adjusted risk ratio for GLP-1RA vs. DPP-4i users.